Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial.

Citation metadata

Date: Jan. 6, 2021
From: BMC Research Notes(Vol. 14, Issue 1)
Publisher: BioMed Central Ltd.
Document Type: Report
Length: 2,411 words
Lexile Measure: 1330L

Document controls

Main content

Abstract :

Objectives To examine the presence of the time-dependent effect of metronomic chemotherapy for the treatment of older patients with acute myeloid leukemia (AML) who were unfit for standard chemotherapy and to reanalyze the data using an appropriate statistical approach in the presence of non-proportional hazards, the restricted mean survival time (RMST). Results This was a secondary analysis of a multi-center, open-label, randomized controlled trial, which was conducted in seven tertiary care hospitals across Thailand. A total of 81 unfit AML patients were randomized into two treatment groups, metronomic chemotherapy and palliative treatment. The hazard ratio of metronomic chemotherapy over palliative treatment was time-dependent. At three landmark time points of 90, 180, 365 days, the restricted mean survival time differences were 13.3 (95% CI 1.9-24.7) days, 28.9 (95% CI 3.3-54.4) days, and 40.4 (95% CI - 1.3 to 82.0) days, respectively. With non-proportional hazards modeling and RMST analysis, we were able to conclude that metronomic chemotherapy is a potentially effective alternative treatment for elderly AML patients who were medically unfit for intensive chemotherapy. In the future clinical trials, non-proportional hazards should be carefully inspected and properly handled with appropriate statistical methods. Trial registration Randomized clinical trial TCTR20150918001; registration date: 15/09/2015. Retrospectively registered Keywords: Leukemias, Maintenance chemotherapy, Survival, Proportional hazard model

Source Citation

Source Citation   

Gale Document Number: GALE|A650590775